Table 6.
Distribution of HFE-variants in IPSS-R categories
| IPSS-R subgroup | HFE-variant, subjects (n) in subgroup (%) | ||||
|---|---|---|---|---|---|
|
| |||||
| C282Y | H63D | S65C | Heterozygous* | all variants+ | |
| Very Low risk | 0/15 (0%) | 5/15 (33.3%) | 0/15 (0%) | 0/15 (0%) | 5/15 (33.3%) |
| Low Risk | 4/58 (6.9%) | 18/58 (31%)** | 2/58 (3.4%) | 1/58 (1.7%) | 25/58 (43.1%) |
| Intermediate risk | 1/23 (4.3%) | 5/23 (21.7%) | 0/23 (0.0%) | 2/23 (8.7%) | 8/23 (34.8%) |
| High risk | 2/31 (6.5%) | 8/31 (25.8%) | 1/31 (3.2%) | 1/31 (3.2%) | 12/31 (38.7%) |
| Very high risk | 1/17 (5.9%) | 2/17 (11.8%) | 0/17 (0%) | 0/17 (0%) | 3/17 (17.6%) |
+
Due to missing parameters only 145 patients were included for IPSS-R subgroup analysis.
*
Heterozygous for HFE-variants C282Y and H63D.
**
1/58 (1.7%) homozygous.
Abbreviations: IPSS-R, revised international prognostic scoring system.